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Not many years ago the main purpose of "com­
plement" seemed to be to drill holes in sheep eryth­
rocytes. In the classic experiment which was part of 
every medical student's microbiology laboratory ex­
perience, a magic stuff called complement, somewhat 
mysteriously obtained from guinea pigs. was either 
"fixed" or not "fixed" and the sheep cells either not 
lysed or lysed accordingly.'That was about all there 
was to know about complement, and all one needed 
to know. 
Today the term "complement" embodies a 
group of plasma proteins which react in a complex 
sequence to mediate a variety of inflammatory ef­
fects, including changes in vascular permeability, the 
attraction of polymorphonuclear or mononuclear 
leukocytes, the enhancement of phagocytosis. and 
damage to cell membranes and osmotic lysis such as 
the sheep erythrocyte suffered in the complement fix­
ation test. These complement proteins rival the in­
trinsic coagulation scheme in complexity and re­
semble it in mechanism, that is. the complement 
proteins normally circulate in the plasma in an in­
active or precursor form, and when appropriately 
stimulated, usually during an immunologic reaction, 
become transformed into active enzymes, or pro­
teases. These proteases act upon their natural sub­
strates (other members of the complement system) in 
an orderly and predetermined sequence of limited 
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proteolytic reactions which are often compared to a 
"cascade" or "waterfall." Cleavage of one com­
ponent leads to the activation of the next component, 
and so forth. Natural inhibitors or inactivators also 
present in plasma serve to modulate or damp this 
cascade system and prevent its getting out of control. 
In fact, congenital deficiency of one of these inhib­
itors, the Cl Inhibitor, leads to uncontrolled activa­
tion of the system and recurrent swelling of the sub­
epithelial tissues of the skin, respiratory and 
gastrointestinal tracts.2 
Biochemical Pathways.•-• 
Two pathways for activation. the classic and 
alternative (properdin ), initiate the terminal attack 
sequence which elaborates most of the biologic activi­
ties associated with complement. The classic pathway 
is activated by immune complexes containing IgG or 
lgM immunoglobulins and their associated antigens. 
The properdin pathway is activated by certain kinds 
of repeating polysaccharides such as pneumococcal 
polysaccharide, or the bacterial lipopolysaccharide of 
gram-negative endotoxin: immune complexes con­
taining lgA may also activate the properdin system. 
Regardless of which pathway is activated, both 
result in the cleavage of C3 and CS. Peptides released 
from these components, C3a and CSa, are anaphy­
latoxins capable of releasing histamine from mast 
cells and thereby influencing local vascular per­
meability. CSa also releases lysosomal enzymes and 
presumably other granular contents from poly­
morphonuclear leukocytes. Both C3a and CSa have 
chemotactic activity as well, the latter being more 
active in most systems: the trimolecular complex 
formed from CS, C6, and C7 is also chemotactic. 
Immune complexes to which complement, especially 
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C3b, has become bound adhere to poly­
morphonuclear neutrophils, mononuclear cells and 
B-lymphocytes. Although the functional significance 
of these binding phenomena is not yet entirely clear, 
enhanced phagocytosis by mononuclear or poly­
morphonuclear cells is certainly one consequence. 
Formation of a multimolecular complex involving 
CS, C6, C7, C8, and C9 leads to the membrane dam­
age and osmotic lysis which have become the hall­
marks of complement activation. 
Metabolism of Complement Proteins. 
One result of the proteolysis of the complement 
proteins during their activation is that they sub­
sequently become recognizable as "altered" or "for­
eign" by the body and are rapidly cleared from the 
circulation. Although some compensatory increases 
in synthesis may occur, the result is usually a fall in 
plasma level. Thus, an ongoing immunologic event 
( or disease) which is activating the complement sys­
tem in vivo may be manifested as a fall in the serum 
or plasma level of one or more of the complement 
proteins. In reverse fashion, as the complement-acti­
vating stimulus or disease abates, this may be paral­
leled by a return towards normal in the complement 
levels. 
Determinations of Complement in the Clinical Pa­
thology Laboratory. 
In principle, there are two ways of measuring 
complement: (I) by its activity in the reaction it ca­
talyzes, for example, the total hemolytic complement 
or CHSO, which measures the result of the interaction 
of all nine of the classic complement components or 
(2) by its antigenicity, as a protein in an immunoas­
say which takes advantage of the complement pro­
tein's capacity to react with monospecific antibody 
directed against it. In practice, although total he­
molytic complement or CHSO determinations are 
available in some institutions, immunoassays (usually 
radial immunodiffusion) are most frequently avail­
able. Materials for these are offered in the form of 
kits for use in the clinical pathology laboratory by a 
number of commercial suppliers. 
A few comments are in order about the radial 
immunodiffusion determinations for complement 
components available in most hospitals. 
I) Radial immunodiffusion, by its very nature, 
is not nearly as precise a determination as 
most physicians have come to expect from 
clinical laboratories. Under the best condi­
tions, the coefficient of variation of the tesl. is 
likely to be 8% or greater, more than twice 
that of commonly available clinical chemistry 
or hematologic procedures. Thus in inter­
preting the results of the test, the physician 
must take into account this reduced preci­
sion, for example, a "fall" in C3 level from 
I 45 to I 30 mg/ I 00 ml from one day to the 
next may reflect only laboratory variation. 
2) There are no widely available standards, so 
that considerable variation in absolute values 
obtained by kits from different suppliers or 
even in lots of kits from the same supplier 
may be observed. This should not be a prob­
lem if results are referred to a normal range 
collected at the institution in which the test is 
being performed, and if appropriate internal 
standards, maintained at the institution, are 
assayed in parallel with the test samples. If 
the "normal ranges" provided with the kits 
are accepted as verbatim, and if independent 
checks of the performance of the kits are 
neglected, then unreliable data may result. 
3) As for other plasma proteins, the range of 
normal for complement proteins is quite 
broad, usually in the vicinity of± 50% of the 
mean value for the population. Thus changes 
in levels in a single patient over a period of 
time may often be more helpful and easier to 
interpret than are comparisons with some ab­
solute range of normal. For example. a pa­
tient with suspect systemic lupus erythema­
tosus whose C4 level fell from 70 mg/ I 00 ml 
to 30 mg/JOO ml within two weeks might be 
cause for alarm, even though the latter value 
was still "within the range of normal." 
4) The most widely available test for a com­
plement component (C3) is not necessarily 
the most desirable. Its availability is directly 
related to the fact that C3 is by far the most 
plentiful of the complement components. the 
easiest to purify. and therefore the easiest to 
make antibody against for use in a radio­
immunoassay. Measurements of C3 were 
therefore widely available from commercial 
sources several years in advance of measure­
ments of other components. Most workers 
would agree today, however, that measure­
ments of C4 are likely to be more sensitive to 
minor episodes of in vivo complement activa­
tion. and that a good "routine" complement 
screen would include measurements of C4, 
C3, and possibly CHSO. 
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5) The immunoassays do not distinguish be­
tween native protein and that which has par­
ticipated in complement activation and lost 
its activity but not its immunogenicity. They 
are reliable, therefore, only in instances in 
which substantial amounts of cleaved, in­
active protein would not be expected. Altered 
complement proteins are cleared within a few 
hours from the plasma space, and the finding 
of altered inactive protein in plasma requires 
special techniques to detect the small 
amounts which are present. In contrast, how­
ever, altered inactive protein may persist for 
much longer times in joint spaces or pleural 
spaces, so that radial immunodiffusion deter­
minations of C3 or C4 in synovial or pleural 
fluid are of very little value. Recent studies 
have shown that measurements of C4 in cere­
brospinal fluid are similarly of little diagnos­
tic value with respect to the presence or ab­
sence of central nervous system involvement 
in systemic lupus erythematosus. 
Clinical Significance. 
Given the knowledge that the complement sys­
tem may be activated in vivo by immunologic dis­
eases, and that simple and reliable methods for mea­
suring complement levels are now widely available, 
how can the practitioner best use this information? 
What are the diseases in which complement measure­
ments are likely to be of help, either in diagnosis or in 
following the course of the patient? The answer is 
simple: any disease in which the physician suspects 
that circulating immune complexes may be playing a 
pathogenetic role. A few of them are listed in the Table. 
Systemic lupus erythematosus is the disease 
which is perhaps most commonly associated with 
hypocomplementemia, but it is well to bear in mind 
that other diseases in which circulating antigen-an-
TABLE 
Diseases in which Complement Determinations May Provide Useful 
Diagnostic or Therapeutic Information 
Systemic lupus erythematosus 
Rheumatoid arthritis (with systemic vasculitis) 
Hypersensitivity angiitis 
Angioedema 
G lomerulonephritis 
Subacute bacterial endocarditis 
Hepatitis 
Essential mixed cryoglobulinemia 
ti body complexes may be found may also give rise to 
hypocomplementemia. Among these would be in­
cluded any cause of "chronic antigenemia," for ex­
ample, subacute bacterial endocarditis, hepatitis B 
surface antigenemia, infected atrioventricular shunts, 
recurrent gram-negative sepsis, recurrent viremias 
such as dengue hemorrhagic fever, or recurrent para­
sitemia, such as falciparum malaria. Other diseases of 
unknown etiology may be associated with hypo­
complementemia, such as essential mixed cryoglo­
bulinemia, or certain kinds of nephritis (which in 
contrast to all the diseases mentioned above which 
are likely to have low C4, and sometimes low C3, 
usually have only low C3, suggesting direct alterna­
tive pathway activation). The symptom of "angioed­
ema" is infrequently associated with hypocomple­
mentemia, but a screening test should be done for C4, 
which is low in almost all cases of hereditary angioed­
ema. especially since very effective treatment for this 
disease is now available. 
In most instances in which hypocomplemen­
temia is found in association with the disease, im­
provements in complement levels are often early and 
reliable indices that the disease is ameliorating either 
spontaneously or as a result of therapy. 
Thus, by applying his understanding of "com­
plement fixation," obtained in the classical micro­
biology laboratory experiment, to human diseases in 
which "complement fixation" appears to be occur­
ring in vivo, today's physician has achieved a useful 
diagnostic tool and therapeutic index in the measure­
ment of complement components in disease. 
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